The Top 5 Biosimilar Articles for the Week of March 7

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of March 7, 2022.

Number 5: AbbVie settled outstanding lawsuits, including International Trade Commission (ITC) case, with Alvotech, giving Alvotech the green light to launch its high-concentration, citrate-free adalimumab biosimilar referencing Humira in July 2023, pending FDA approval.

Number 4: The FDA has approved Releuko (filgrastim-ayow), a filgrastim biosimilar referencing Neupogen developed by Amneal Pharmaceuticals and Kashiv Biosciences. The biosimilar marks the third filgrastim biosimilar to be approved for the US market.

Number 3: Shanghai Henlius Biotech announced a commercialization agreement with Getz Pharma Limited for an adalimumab biosimilar for various African and Asian countries.

Number 2: As part of a new partnership between the companies, Biocon Biologics announced that it will acquire Viatris’ entire biosimilar portfolio for up to $3.3 billion.

Number 1: The FDA has accepted biologics license applications (BLAs) for interchangeability status from Alvotech and Pfizer regarding their respective adalimumab biosimilars referencing Humira.

To read all of these articles and more, visit centerforbiosimilars.com.